Consultant in Medical Oncology
Qualifications:
MD, PhD, FRCP
GMC number:
4077392
Membership and appointments:
Director of Clinical Research, The Clatterbridge Cancer Centre
Professor of Immuno-Oncology, University of Liverpool
Visiting Professor, University of Southampton
Adjunct Professor, La Jolla Institute for Immunology
European Society of Medical Oncology
Fellow of the Royal College of Physicians
American Society of Clinical Oncology
Cancer Immunotherapy Collaborative (Germany)
CIMT Immunoguiding Program steering group (European Collaborative)
European Academy for Tumor Immunology (EATI)
National Cancer Research Clinical Trials Melanoma Group
Specialty:
Prof Christian Ottensmeier graduated and began his training at the Westfälische Wilhelms-University in Münster, Germany. After a training fellowship at the Dana Farber Cancer Institute in Boston (USA) he moved to Southampton where he completed his oncology training.
Following completion of his doctorate on the molecular immunology of B-cells in the laboratory of Freda Stevenson, he became a consultant in medical oncology at Southampton University Hospitals and senior lecturer at the University of Southampton in 2001.
In 2007 he was appointed Chair in Experimental Cancer Medicine in Southampton and in 2019 to an associate professorship at the La Jolla Institute for Immunology in California.
Prof Ottensmeier joined the University of Liverpool and the Head and Neck Institute as Professor of Immuno-Oncology in August 2020. He was appointed Director of Clinical Research at The Clatterbridge Cancer Centre in 2022.
Christian’s core interest is the understanding and improvement of immune responses in patients, with the aim of developing immunotherapies against solid cancers. His clinical focus is in head and neck and lung cancers. He manages a broad portfolio of clinical trials in solid cancers and has co-developed a number of national studies in melanoma and lung cancer.
Prof Ottensmeier has served on a number of national and international peer review committees, as well as advisory boards and data and safety monitoring boards for industry-led studies.